help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hasegawa, N.
Right arrow Articles by Raffin, T. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hasegawa, N.
Right arrow Articles by Raffin, T. A.

Am. J. Respir. Crit. Care Med., Vol 155, No. 3, 03 1997, 928-936.

The effects of post-treatment with lisofylline, a phosphatidic acid generation inhibitor, on sepsis-induced acute lung injury in pigs

N Hasegawa, Y Oka, M Nakayama, GJ Berry, S Bursten, G Rice and TA Raffin
Division of Pulmonary and Critical Care Medicine, Stanford University Medical Center, CA 94305-5236, USA.

The effects of lisofylline [(R)-1-(5-hydroxyhexyl)-3,7- dimethylxanthine] (LSF), an inhibitor of de novo phosphatidic acid (PA) generation, on sepsis-induced acute lung injury was studied using Hanford minipigs weighing 18 to 25 kg. Sepsis was induced by an intravenous infusion of Pseudomonas aeruginosa (1 x 10(6)/colony- forming units/kg/min over 2 h). Saline was used as the control vehicle. Six groups were studied: saline control group (SALINE: n = 5); sepsis control group (SEPSIS: n = 5); LSF control group (LSF: n = 5), which received a 25-mg/kgbolus of LSF 30 min before time zero followed by continuous infusion of 10 mg/kg/h throughout the study; LSF-treated septic groups, which were treated with LSF 30 min prior to sepsis (Pre: n = 5), 1 h postonset (Post-1 h: n = 8) or h postonset (Post-2 h: n = 8) of the bacterial infusion. Hemodynamics PaO2, neutrophil counts, and plasma porcine tumor necrosis factor-alpha concentrations were monitored for 6 h. After the minipigs were killed, lung tissue was sampled to measured wet-to-dry weight ratio (W/D), tissue albumin index (TAI), thiobarbituric acid-reactive material content (TBARM), and myeloperoxidase (MPO) activity. Compared with the SALINE group, the SEPSIS group showed significant systemic hypotension, pulmonary hypertension, arterial hypoxemia, neutropenia, and increase in TNF- alpha, MPO activity, W/D, TBARM, and TAI. LSF treatment attenuated sepsis-induced pulmonary hypertension, neutropenia, and hypoxemia, and increased MPO activity and lung injury measurements in the Pre and Post- 1 h groups, but its efficacy was blunted in the Post-2 h group. Plasma TNF-alpha was decreased only in the Pre group. Thus, inhibition of intracellular PA generation through de novo pathways attenuates sepsis- induced acute lung injury.


This article has been cited by other articles:


Home page
J Intensive Care MedHome page
M. Cepkova and M. A. Matthay
Pharmacotherapy of acute lung injury and the acute respiratory distress syndrome.
J Intensive Care Med, May 1, 2006; 21(3): 119 - 143.
[Abstract] [PDF]


Home page
J. Biol. Chem.Home page
H.-K. Lim, Y.-A. Choi, W. Park, T. Lee, S. H. Ryu, S.-Y. Kim, J.-R. Kim, J.-H. Kim, and S.-H. Baek
Phosphatidic Acid Regulates Systemic Inflammatory Responses by Modulating the Akt-Mammalian Target of Rapamycin-p70 S6 Kinase 1 Pathway
J. Biol. Chem., November 14, 2003; 278(46): 45117 - 45127.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
C. L. S. George, G. Fantuzzi, S. Bursten, L. Leer, and E. Abraham
Effects of lisofylline on hyperoxia-induced lung injury
Am J Physiol Lung Cell Mol Physiol, May 1, 1999; 276(5): L776 - L785.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. J. Bright, C. Du, M. Coon, S. Sriram, and S. J. Klaus
Prevention of Experimental Allergic Encephalomyelitis via Inhibition of IL-12 Signaling and IL-12-Mediated Th1 Differentiation: An Effect of the Novel Anti-Inflammatory Drug Lisofylline
J. Immunol., December 15, 1998; 161(12): 7015 - 7022.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 1997 American Thoracic Society